Loading
Heart Failure With Reduced Ejection Fraction / ketone ester · Phase 2 Trial
ClinicalTrials.gov · September 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registry record for a completed but unreported study of a ketone ester dietary supplement (DeltaG) in 25 patients with heart failure with reduced ejection fraction. The study measured maximal and submaximal exercise capacity as primary outcomes but no results are posted in this registry entry, precluding assessment of efficacy or safety.
Phase 2, Interventional, Randomized, Crossover, Triple masking, Treatment purpose. Heart Failure With Reduced Ejection Fraction; age from 18 Years. Intervention: ketone ester. Compared with: placebo — Placebo Comparator. n = 25. 1 site: United States.
This is a Phase 2 registry record for a completed but unreported study of a ketone ester dietary supplement (DeltaG) in 25 patients with heart failure with reduced ejection fraction. The study measured maximal and submaximal exercise capacity as primary outcomes but no results are posted in this registry entry, precluding assessment of efficacy or safety.
Results are not posted in this registry record; no efficacy, safety, or adverse event data are available.
No clinical impact can be assessed from this registry record, as no outcome data are reported. Clinicians should await publication of the completed trial results to evaluate the effect of ketone ester supplementation on exercise capacity in this population.
Phase 2 single-arm dietary supplement study with planned enrollment of 25 participants testing a novel ketone ester intervention in heart failure; no results are posted in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record, as no outcome data are reported. Clinicians should await publication of the completed trial results to evaluate the effect of ketone ester supplementation on exercise capacity in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06195982). This is a study registration, not published results. Lead sponsor: Duke University. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 25 participants (ACTUAL). Conditions: Heart Failure With Reduced Ejection Fraction. Interventions: DIETARY_SUPPLEMENT: ketone ester; DIETARY_SUPPLEMENT: placebo. Primary outcome measures: Maximal exercise capacity , 60 minutes after the intervention; Submaximal exercise capacity , 30 minutes after the intervention. Brief summary: The purpose of this study is to understand the effects of a ketone drink on exercise capacity and other cardiovascular parameters in patients with heart failure. In heart failure, patients are limited in their ability to do all the things they want to do, and exercise as much as they would like, due to becoming tired and short of breath early. There may be several reasons why these symptoms occur. This study is assessing whether the ketone drink can improve these symptoms. This drink has been given status by Food and Drug Administration as "generally regarded as safe". The use of DeltaG in this study is experimental. DeltaG has not been approved by the Food and Drug Administration (FDA) for the use being evaluated in this study.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.